What does Evogene do?
Evogene Ltd. is an Israeli computational-chemistry company listed on Nasdaq and the Tel Aviv Stock Exchange under EVGN. After operating as a broader computational-biology group, management is concentrating resources on ChemPass AI, a generative-AI platform designed to discover and optimize small molecules for pharmaceutical and agricultural applications. It supplies computational design, screening and lead-optimization capabilities to partners while advancing selected internal programs.
How should a reader classify the company?
Evogene sits between an AI-software platform, a research-services organization and an early-stage biotechnology company. Software-like intellectual property could support high incremental margins if licensing and milestones scale, but the financial statements still resemble an R&D-stage enterprise: irregular revenue, recurring losses and external financing needs. The official company profile presents ChemPass AI as the central engine connecting computational prediction with laboratory validation and partner programs.
Why does Evogene matter despite its small size?
The strategic question is whether specialized chemical intelligence can reduce the costly experimental search involved in finding a viable molecule. ChemPass AI evaluates properties such as potency, selectivity, toxicity, stability, ADME, synthesizability and novelty before a partner commits to extensive wet-lab work. If that prediction layer improves hit quality or shortens optimization cycles, Evogene can participate in valuable programs without funding every downstream clinical trial or agricultural launch itself. The opportunity depends on intellectual-property leverage and partner capital, not current market dominance.
How does Evogene make money?
Evogene’s revenue is project-based rather than subscription-like. It can receive research payments, license consideration, milestone payments and potentially royalties if a discovered molecule reaches market. Agricultural subsidiaries have also generated product revenue, but the 2025–2026 restructuring sharply reduced that activity and made the parent company’s platform economics more central.
Which activities can become material revenue streams?
Why is reported revenue so volatile?
A small number of transactions can dominate a quarter. Q1 2025 included approximately $2.0 million of Casterra seed revenue, while Q1 2026 did not. That explains much of the 85.7% year-over-year revenue decline to $0.334 million in the quarter ended March 31, 2026. The relevant question is whether collaborations produce upfront cash, advance to milestones and create a diversified backlog of funded work.
| Revenue source | Timing | Margin profile | Research implication |
|---|---|---|---|
| Research and collaboration fees | During project execution | Potentially attractive, but scale is unproven | Track funded scope, not announcement count. |
| Licenses and milestones | Event-driven | High incremental margin when earned | Contract triggers and timing drive valuation. |
| Royalties | Only after successful commercialization | Potentially high | Long-dated and unsuitable as near-term base revenue. |
| Seed or product sales | Seasonal and market-dependent | Inventory and production exposure | Separate legacy products from the platform thesis. |
What does Evogene’s first quarter of 2026 show?
The Q1 2026 results show a company with lower operating expenditure but still meaningful cash consumption and financing sensitivity. Revenue fell to $0.334 million for the quarter ended March 31, 2026 from $2.343 million in Q1 2025. Gross profit was $0.204 million, while operating loss was $3.150 million and net loss was $5.896 million. The gap between operating and net loss reflected $2.713 million of net finance expense, including warrant fair-value effects.
Which cost lines changed most?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.334M | $2.343M | Prior-year seed sales created a difficult comparison. |
| Gross profit | $0.204M | $0.826M | Higher percentage margin on a much smaller base. |
| R&D expense | $1.839M | $2.471M | Down 25.6%, reflecting the narrowed operating footprint. |
| General and administrative expense | $1.156M | $1.176M | Only modestly lower and still significant versus revenue. |
| Net finance result | -$2.713M | +$1.126M | Warrant valuation and financing items amplified the net loss. |
| Diluted loss per share | $0.60 | $0.38 | Loss per share widened despite more weighted-average shares. |
What do liquidity and cash burn imply?
The detailed Q1 2026 interim statements reported $8.511 million of cash and $4.543 million of short-term deposits at March 31, 2026. Combined liquidity of $13.054 million equaled roughly 2.43 times current liabilities of $5.364 million. Dividing that liquidity by Q1 2026 operating cash use of $2.954 million gives about 4.4 quarters of mechanical coverage before spending, financing or receipts change. It highlights the importance of milestones and fundraising.
Which turning points shaped Evogene’s current strategy?
Evogene repeatedly tried to convert computational biology into commercial programs, then reversed broad expansion when subsidiary economics strained the balance sheet.
How did the business evolve?
-
2000–2002The activity began within Compugen and was spun out, establishing computation-led biological discovery as the core idea.
-
2007Evogene listed on the Tel Aviv Stock Exchange to fund long-cycle research.
-
2013The U.S. IPO sold 5.75 million shares at $14.75 and raised approximately $84.8 million gross, expanding the capital base for platform development and collaborations.
-
2017–2020The company built a multi-subsidiary model spanning agriculture, microbes and human health. The 2020 rebranding formalized this broader structure.
-
2024A Google Cloud collaboration supported the 38-billion-structure model, while a July 2024 one-for-ten reverse split signaled capital-market pressure.
-
2025Management divested Lavie Bio assets, reduced subsidiary activity, repaid a $10 million SAFE obligation and centered the group on ChemPass AI. The change lowered costs but also removed businesses that had once supplied revenue diversity.
-
2026New collaborations expanded the pipeline, while warrants, listing pressure and activism made governance and dilution operational issues.
What did the 2025 restructuring change?
The restructuring turned a collection of computationally enabled ventures into a focused platform company. Lavie Bio ceased operations after its asset transaction, Biomica licensed its BMC128 program and was not expected to maintain material operations, and Casterra was reduced to a Brazil-focused seed opportunity. Annual operating expenses fell from $22.001 million in FY2024 to $13.793 million in FY2025, a 37.3% decline. The trade-off is concentration: ChemPass AI now carries most of the strategic burden.
What gives ChemPass AI a competitive advantage?
ChemPass AI’s proposed advantage is a domain-specific combination of generative design, property prediction and experimental feedback. Rather than generating molecules from text alone, the platform is intended to optimize multiple chemical and biological constraints simultaneously. Evogene says its foundation model achieved 90% design precision in a company-defined test versus approximately 30% for traditional GPT-style models. The figure is useful as evidence of internal progress, but it is not the same as independent clinical or commercial validation.
Which resources are genuinely differentiated?
Where could the moat fail?
A durable moat requires more than a large model. Pharmaceutical companies, agricultural-chemical groups, contract research organizations and specialized AI-discovery firms can build or license competing capabilities. Some customers may prefer internal models to protect proprietary data, while others may demand evidence that computational predictions produce experimentally superior compounds. Evogene’s position becomes stronger when partner results create proprietary feedback loops, patents protect generated matter, and successful programs make the platform costly to replace. It weakens if collaboration announcements do not convert into repeatable fees, milestones or differentiated molecules.
ChemPass AI may reduce the search cost of chemistry, but Evogene’s economic moat will be measured by validated molecules and contract cash flows—not by model scale alone.
Who are Evogene’s competitors, and how is the company positioned?
Evogene competes for discovery budgets and partner attention against four groups: internal computational-chemistry teams at large pharmaceutical and crop-science companies; specialized AI drug-discovery platforms; traditional medicinal-chemistry and contract-research providers; and academic centers that combine structural biology with screening. Its advantage is flexibility across human health and agriculture; its disadvantage is limited scale versus customers and rivals with larger budgets and datasets.
| Alternative | Why customers use it | Evogene response | Pressure point |
|---|---|---|---|
| In-house discovery teams | Data control, integration and existing scientific staff | Offer specialized models and external capacity without building a full platform internally | Large customers can replicate tools or restrict data sharing. |
| AI-native discovery companies | Purpose-built models, proprietary datasets and broad pipelines | Differentiate through chemistry-focused multi-parameter optimization and agriculture experience | Competitors may have greater capital and clinical validation. |
| CROs and medicinal chemistry vendors | Established laboratory execution and fee-for-service capacity | Use computation to reduce compounds synthesized and tested | Customers may prioritize end-to-end execution over software differentiation. |
| Academic discovery centers | Disease expertise, grants and specialist assays | Partner rather than compete; Evogene’s Tel Aviv University initiative follows this model | Academic programs may move slowly and offer limited near-term revenue. |
What is the practical market-position conclusion?
Evogene should be viewed as a focused challenger, not a dominant platform. Its best strategic position is to become the computational layer inside partner-led programs where the counterparty supplies target biology, assays, development funding and commercialization capability. The July 2026 antifungal model launch at AgPlenus illustrates vertical specialization: the Antifungal Potency Predictor estimates activity from chemical structure before synthesis and testing. Such applications can create credibility if they produce field-relevant candidates, but they remain program-level evidence rather than proof of market-wide leadership.
How financially strong is Evogene?
Evogene’s balance sheet is streamlined after the 2025 restructuring, but the company is not self-funding. FY2025 revenue was $3.853 million, down 30.9% from $5.577 million in FY2024. A $2.180 million inventory impairment produced a $0.241 million gross loss in FY2025. Operating expenses fell sharply, yet operating loss remained $14.034 million and net operating cash use was $13.502 million. The annual report filed through the SEC annual-report filing provides the broader risk and business context.
What changed between FY2024 and FY2025?
| Metric | FY2025 | FY2024 | Analytical signal |
|---|---|---|---|
| Revenue | $3.853M | $5.577M | Lower project and product revenue. |
| Total operating expenses | $13.793M | $22.001M | Down 37.3% after portfolio narrowing and headcount reductions. |
| Operating loss | $14.034M | $18.804M | Improved 25.4%, though still large relative to revenue. |
| Net loss | $7.827M | $18.054M | Improved 56.6%, helped by discontinued-operation gains including the Lavie Bio asset sale. |
| Operating cash flow | -$13.502M | -$19.700M | Cash burn improved 31.5%, but remained substantial. |
| Cash and equivalents | $12.956M | $15.301M | Down 15.3% at year-end despite asset-sale inflows and equity financing. |
How does capital allocation affect survival and upside?
The official FY2025 results also show $17.738 million of net investing cash inflow, largely associated with discontinued operations, and $6.602 million of net financing cash outflow. Asset sales and liability repayment can temporarily obscure operating burn. Capital allocation should be judged by whether research spending supports funded programs and financing preserves per-share value.
Who owns EVGN stock, and why does governance matter?
Evogene has one class of ordinary shares, with one vote per share and no cumulative voting. The small capitalization nevertheless lets a concentrated holder gain meaningful influence without owning a majority. In July 2026, Pure Capital and Invest Pro disclosed a coordinated activist position and sought an extraordinary general meeting to replace most directors.
What does the latest official ownership filing show?
| Holder or group | Latest disclosed economic position | Voting influence | Source period | Why it matters |
|---|---|---|---|---|
| Pure Capital | 1,672,000 ADS plus 56,100 ordinary shares | Approximately 13.03% sole dispositive power; shared vote within the group | Schedule 13D amendment, July 20, 2026 | Largest disclosed activist participant. |
| Invest Pro | 500,000 ADS | Approximately 3.77% sole dispositive power; shared vote within the group | Schedule 13D amendment, July 20, 2026 | The voting agreement magnifies influence. |
| Reporting group | 2,172,000 ADS plus 56,100 ordinary shares | Approximately 16.81% shared voting power | Based on at least 13,258,521 shares as of July 17, 2026 | Meaningful influence, though actual percentage may be lower. |
| Board | Six directors, including CEO Ofer Haviv | Annual election by ordinary shareholder vote | Company leadership disclosure, July 2026 | The extraordinary meeting challenges leadership continuity. |
The Schedule 13D amendment is more decision-useful than an ownership aggregator because it discloses the voting agreement, acquired securities and calculation basis. Evogene’s July 2026 governance update warned that the campaign could distract management, unsettle partners, increase costs, affect fundraising and complicate talent retention. The filing also raised authorized at-the-market issuance by $361,613 to $3.288 million, underscoring financing needs.
Board chair Nir Nimrodi, CEO Ofer Haviv and other directors on the company leadership page oversee a strategy that is still being implemented. A board transition could accelerate transactions or interrupt partner negotiations. Governance can therefore alter cash policy, financing terms and commercialization speed.
What opportunities and risks could change Evogene’s story?
Evogene’s outcomes are asymmetric: one material license could transform a quarter, while delays leave costs largely unchanged. Technical progress must therefore be separated from financing and governance execution.
Which metrics should researchers monitor next?
| Risk | Financial pathway | Evidence that would reduce concern |
|---|---|---|
| Scientific and validation risk | R&D produces no milestones or licenses. | Independent assays and partner-funded advancement. |
| Partner concentration and timing | Irregular receipts create revenue and liquidity volatility. | Multiple funded projects with staggered milestones. |
| Dilution and capital access | Shares and warrants dilute future upside. | Lower burn and stronger financing terms. |
| Governance disruption | Distraction or turnover may delay collaborations. | A clear board outcome and stable execution. |
| Agricultural execution | Seasonality and field performance can damage economics. | Trials, purchase commitments and controlled inventory. |
| Israel and operational continuity | Geopolitical events may affect operations and financing. | Diversified collaborators and continuity planning. |
Why does Evogene matter for valuation, and what is the key takeaway?
A steady-state discounted cash-flow model is a poor starting point because revenue is small, free cash flow is negative and milestones are uncertain. A better approach starts with liquidity and burn, then probability-weights collaborations and downstream economics. Scientific optionality may be large, but financing can transfer part of the upside to new capital providers.
Which variables belong in an EVGN valuation model?
| Driver | Model treatment | Current evidence | What changes value most |
|---|---|---|---|
| Cash runway | Start with liquidity, burn and obligations | $13.054M liquidity at March 31, 2026 | Burn, distributions, upfront payments and financing terms |
| Platform revenue | Scenario-based fees and license income | $0.334M Q1 2026 revenue; limited recurring base | Size and duration of funded programs |
| Milestones and royalties | Probability-adjusted by stage and time | Multiple disclosed programs, but few mature cash-generating assets | Validated leads, licenses and funded advancement |
| Operating leverage | Estimate profit against the reduced fixed-cost base | FY2025 operating expenses fell 37.3% | Growth without rebuilding prior costs |
| Dilution | Model warrants, ATM and future equity | 10.413M shares outstanding at March 31, 2026; warrant activity continued | Capital raised per share and value created |
| Terminal risk | Use explicit failure scenarios rather than a smooth perpetuity | Pre-scale model, scientific uncertainty and governance pressure | Validation, durable contracts and positive free cash flow |
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.